Tumor-associated B Cells and Humoral Immune Response in Head and Neck Squamous Cell Carcinoma
Overview
Authors
Affiliations
B lymphocytes are important players in immune responses to cancer. However, their composition and function in head and neck squamous cell carcinoma (HNSCC) has not been well described. Here, we analyzed B cell subsets in HNSCC (n = 38), non-cancerous mucosa (n = 14) and peripheral blood from HNSCC patients (n = 38) and healthy controls (n = 20) by flow cytometry. Intratumoral B cells contained high percentages of activated (CD86), antigen-presenting (CD86/CD21) and memory B cells (IgD/CD27). T follicular helper cells (CD4/CXCR5/CD45RA/CCR7) as key components of tertiary lymphoid structures and plasma cells made up high percentages of the lymphocyte infiltrate. Percentages of regulatory B cell varied depending on the regulatory phenotype. Analysis of humoral immune responses against 23 tumor-associated antigens (TAA) showed reactivity against at least one antigen in 56% of HNSCC patients. Reactivity was less frequent in human papillomavirus associated (HPV) patients and healthy controls compared to HPV negative (HPV) HNSCC. Likewise, patients with early stage HNSCC or MHC-I loss on tumor cells had low TAA responses. Patients with TAA responses showed CD4 dominated T cell infiltration compared to mainly CD8 T cells in tumors without detected TAA response. To summarize, our data demonstrates different immune infiltration patterns in relation to serological TAA response detection and the presence of B cell subpopulations in HNSCC that can engage in tumor promoting and antitumor activity. In view of increasing use of immunotherapeutic approaches, it will be important to include B cells into comprehensive phenotypic and functional analyses of tumor-associated lymphocytes.
Zhao M, Huang W, Huang X, Gu F, Yang L, Wang Y Braz J Med Biol Res. 2025; 58:e14227.
PMID: 39907408 PMC: 11793147. DOI: 10.1590/1414-431X2024e14227.
Nauta I, Nijenhuis D, Ganzevles S, Raaff P, Kloosterman J, Bloemena E Cancers (Basel). 2025; 17(1.
PMID: 39796740 PMC: 11719715. DOI: 10.3390/cancers17010113.
Sonntag M, Stanojevic S, Laban S, Schuler P, Hoffmann T, Brunner C Cells. 2025; 14(1.
PMID: 39791721 PMC: 11720715. DOI: 10.3390/cells14010020.
Yang H, Zhang Z, Li J, Wang K, Zhu W, Zeng Y Int J Mol Sci. 2024; 25(21).
PMID: 39519376 PMC: 11546796. DOI: 10.3390/ijms252111825.
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.
Shi X, Cheng X, Jiang A, Shi W, Zhu L, Mou W Adv Sci (Weinh). 2024; 11(47):e2403423.
PMID: 39509319 PMC: 11653663. DOI: 10.1002/advs.202403423.